PROPOSED SCENARIO PLANNING DEVELOPMENT FOR INDONESIA MULTINATIONAL PHARMACEUTICAL COMPANY IN JAMINAN KESEHATAN NASIONAL (JKN) ERA

• Main Author: TRI NURMALA (NIM 29115458), DEVY
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/26547
• Institution: Institut Teknologi Bandung

Jaminan Kesehatan Nasional is one of the government's flagship programs to provide health services for all residents in Indonesia since 2014. The multinational pharmaceutical companies become one of the actors in supporting the successful of the program by providing innovative medicines. After the implementation, the government suffered losses in financing. <br /> <br /> The objective of this study is to propose a better strategy for pharmaceutical companies in Indonesia in support of the government's national health program. The discussion on this issue will be analyzed from an external point of view by using PESTEL (Political, Economic, Social, Technological, Environment, Legal) and from an Industry perspective using Porter's 5 Forces Analysis. In further analysis for internal use Resources based view, value chain analysis and SWOT (strength, weakness, opportunity, threats). <br /> <br /> The research method is qualitative by collecting data through interview and data observation. Data collection through observation and interviews of decision-makers include government, health workers, patients and the pharmaceutical industry. Scenario planning as a tool for drafting the strategy of multinational pharmaceutical companies within the next five years. In the formulation of a strategy, it is necessary to identify the main driving force, which then generates two important uncertainties, namely the prevailing regulations and the knowledge of the experts. The analysis then proceeded to create four quadrants: Become niche, Invest, Do More and Go Beyond and followed by a narrative for each scenario. <br /> <br /> After the planning scenario analysis is done, it is recommended for human resource development, approaches in terms of drug costs with efficacy, and makes long-term investments with government and health institutions with partnerships.